The crucial role of ABC transporters on TKI accumulation and their activity as a mechanism of resistance in CML led to exploiting some ABC transporter inhibitors to overcome TKI resistance. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.